This is an open-label, single-center, 2 period crossover, PK profile study. Each subject will be randomized to 1 of 2 treatment sequences. Both treatment sequences will be enrolled concurrently.
This is a study of healthy volunteers to demonstrate bioequivalence of two formulations of BG-00012 given in capsule form..
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
80
Bioequivalence of two drug formulations
Research Site
Minneapolis, Minnesota, United States
Area under the plasma concentration curve as a measure of PK.
Time frame: Participants will be followed during the duration of the study, 4 days. Samples taken at -15mins, 30 mins, 60 mins, 90 mins, 2 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 7 hrs, 8 hrs, 10 hrs, 12 hrs
The number of AEs in participants as a measure of safety and tolerability.
Time frame: Participants will be followed during the time of study - an estimated four days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.